| Identification | Back Directory | [Name]
(4-Cyclopropyl-3,4-dihydro-1(2H)-quinoxalinyl)[4-(2,5-dimethylphenoxy)-3-pyridinyl]methanone | [CAS]
1415407-60-1 | [Synonyms]
TC-G 1005
(4-Cyclopropyl-3,4-dihydro-1(2H)-quinoxalinyl)[4-(2,5-dimethylphenoxy)-3-pyridinyl]methanone
Methanone, (4-cyclopropyl-3,4-dihydro-1(2H)-quinoxalinyl)[4-(2,5-dimethylphenoxy)-3-pyridinyl]-
TC G 1005,G protein-coupled Bile Acid Receptor 1,levels,coupled,glucose,TCG 1005,Takeda,inhibit,protein,TC-G 1005,GPBAR1,GPCR19,TGR5,Inhibitor,G-protein coupled receptor 19 | [Molecular Formula]
C25H25N3O2 | [MDL Number]
MFCD30182262 | [MOL File]
1415407-60-1.mol | [Molecular Weight]
399.48 |
| Chemical Properties | Back Directory | [Boiling point ]
564.5±50.0 °C(Predicted) | [density ]
1.253±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
6.35±0.20(Predicted) | [color ]
Off-white to yellow |
| Hazard Information | Back Directory | [Uses]
TC-G 1005 is an agonist required for the activation of Takeda G-protein receptor 5 (TGR5). | [Biological Activity]
Primary Target
TGR5''Reversible: yes | [in vivo]
TC-G 1005 (25-100 mg/kg; a single p.o.) stimulates GLP-1 secretion in imprinting control region (ICR) mice[1].
?
TC-G 1005 (50 mg/kg; a single p.o.) causes a 49% reduction in blood glucose AUC0-120 min in ICR mice[1].
?
TC-G 1005 (50 mg/kg; a single p.o.) signi?cantly reduces blood glucose at 4, 6, 10, and 24 h in db/db mice[1].
?
TC-G 1005 (5 mg/kg; p.o.) exhibits rather low plasma exposure, with a Cmax of 56 ng/mL and a t1/2 of 1.5 in rats[1]. | Animal Model: | Male ICR mice[1] | | Dosage: | 25, 50, 100 mg/kg | | Administration: | A single p.o. | | Result: | Increased the plasma active GLP-1 levels by 31, 96, and 282% at doses of 25, 50, and 100 mg/kg, respectively. |
| [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|